Theodore Schroeder

Theodore R.
Schroeder was the founder of Mallinckrodt Hospital Products, Inc., founded in 2004, where the titles held included President, Chief Executive Officer & Director from 2004 to 2014.
Mr. Schroeder was the founder of Zavante Therapeutics, Inc., founded in 2015, where the titles held included President, Chief Executive Officer & Director from 2015 to 2018.
Current jobs include Director at Sharp Hospital Foundation and Independent Director at Phathom Pharmaceuticals, Inc. starting in 2025.
Former jobs include Vice Chairman at Antimicrobials Working Group from 2021 to 2023; Chairman at Biocom, Inc. from 2015 to 2017; Senior Director-Marketing Hospital Products at Dura Pharmaceuticals, Inc. in 2000; Director at Nabriva Therapeutics Plc from 2023 to 2025; Independent Director at Collegium Pharmaceutical, Inc. from 2016 to 2021; Director at Hyperion Therapeutics, Inc. from 2014 to 2015; Director at Incline Therapeutics, Inc.; Independent Director at Cidara Therapeutics, Inc. from 2014 to 2026; Independent Director at Trius Therapeutics, Inc. from 2012 to 2013; Independent Director at Otonomy, Inc. from 2015 to 2023; Principal at Bristol Myers Squibb Co.; Senior VP-North American Sales & Marketing at Elan Pharmaceuticals LLC from 2002 to 2004.
Education includes undergraduate studies at Rutgers State University of New Jersey.